Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 24, 2015 9:05 PM ET

Capital Markets

Company Overview of MedImmune Ventures, Inc.

Executive Profile

Peter S. Greenleaf

Chief Executive Officer and Director, Sucampo Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 7 different industries.

See Board Relationships
44$5,650,759
As of Fiscal Year 2014

Background

Mr. Peter S. Greenleaf has been the Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since March 03, 2014. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. Mr. Greenleaf served as President of MedImmune, LLC (also known as MedImmune, Inc.). Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, ...

Corporate Headquarters

One MedImmune Way
Gaithersburg, Maryland 20878

United States

Phone: 301-398-3000
Fax: 301-398-8170

Board Members Memberships

Former Director
Director
Former Chief Executive Officer and Director
Former Director
2010-N/A
Former Director
2014-Present
Chief Executive Officer and Director

Education

MBA
Saint Joseph's University
BA
Western Connecticut State University

Other Affiliations

Annual Compensation

Salary$440,192
Total Annual Compensation$440,192

Stocks Options

All Other Compensation$2,025
Unexercisable Options$1,000,000
Unexercisable Options Value$6,656,000
Total Value of Options$6,656,000
Total Number of Options$1,000,000

Total Compensation

Total Annual Cash Compensation$811,979
Total Short Term Compensation$440,192
Other Long Term Compensation$2,025
Total Calculated Compensation$5,650,759
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$621.0K
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune Ventures, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.